Healthcare Industry News: stomach cancer
News Release - April 27, 2007
EndoGastric Solutions Announces First Endoluminal Fundoplication Procedures in Japan: Kyushu University Performs First EsophyX CasesREDMOND, Wash., April 27 (HSMN NewsFeed) -- EndoGastric Solutions, the world leader in endoluminal intragastric surgery, announces that Professor Makoto Hashizume and his team of endoscopic surgeons completed the first Endoluminal Fundoplication procedure using the EsophyX device in Japan on April 25th at the Kyushu University Hospital.
Professor Hashizume said, "We can report that our first endoluminal case was a success from a procedure standpoint. Although GERD is a smaller procedure market as compared to western countries, EndoGastric Solutions' incisionless surgical technology provides a platform for device iteration to treat diseases that are more common in Japan including stomach cancer. This first procedure opens the door to this new incisionless method which will be very attractive to the Japanese medical community. The future of endoluminal surgery in Japan will be very exciting."
Following positive six-month follow-up results from their Phase I European clinical trials, EsophyX ELF was first commercially introduced in a controlled launch to the European market in June of 2006. Earlier this month, the company reported 92% of patients in their pivotal trial were no longer taking daily Proton Pump Inhibitors (PPIs).
"We are very happy to have a leading surgeon at such a prestigious university hospital initiate our Japanese experience with endoluminal surgery," said Thierry Thaure, EndoGastric Solutions President and Chief Executive Officer. "Kyushu University is recognized throughout the world as a trend-setting hospital and we hope to soon have other hospitals follow them once we identify our distribution partner in Japan."
About EndoGastric Solutions, Inc.
EndoGastric Solutions(TM) is a pioneer in endoluminal procedures for the treatment of gastrointestinal diseases, including GERD and obesity. EndoGastric Solutions' mission is to utilize the most current wisdom in gastroenterology and surgery to develop new transoral procedures and products to address the largest unmet needs in gastrointestinal diseases. EndoGastric Solutions' technologies involve modifying current open surgical and/or laparoscopic approaches by using transoral access instead of abdominal incisions. The company designs and manufactures single-use instruments that will enable these incisionless solutions, and focuses on clinically based products for use by gastroenterologists and surgeons.
StomaphyX is available in the United States. EsophyX is not available for sale or use in the United States. Both devices are CE marked and available in the European Union.
For more information about EndoGastric Solutions, Inc., EsophyX and StomaphyX please visit:
In the US: http://www.endogastricsolutions.com
In the EU: http://www.egseurope.eu
Other locations throughout the globe: http://www.egsglobal.net
Source: EndoGastric Solutions
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.